BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 34289936)

  • 1. Characterisation of isocitrate dehydrogenase gene mutant WHO grade 2 and 3 gliomas: MRI predictors of 1p/19q co-deletion and tumour grade.
    Doig D; Kachramanoglou C; Dumba M; Tona F; Gontsarova A; Limbäck C; Jan W
    Clin Radiol; 2021 Oct; 76(10):785.e9-785.e16. PubMed ID: 34289936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
    Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
    Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
    Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
    Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting 1p/19q codeletion status using diffusion-, susceptibility-, perfusion-weighted, and conventional MRI in IDH-mutant lower-grade gliomas.
    Yang X; Lin Y; Xing Z; She D; Su Y; Cao D
    Acta Radiol; 2021 Dec; 62(12):1657-1665. PubMed ID: 33222488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas.
    Zhao K; Sun G; Wang Q; Xue Z; Liu G; Xia Y; Yao A; Zhao Y; You N; Yang C; Xu B
    Acad Radiol; 2021 Jul; 28(7):e189-e198. PubMed ID: 32359929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MRI Scoring Systems for Predicting Isocitrate Dehydrogenase Mutation and Chromosome 1p/19q Codeletion in Adult-type Diffuse Glioma Lacking Contrast Enhancement.
    Kang KM; Song J; Choi Y; Park C; Park JE; Kim HS; Park SH; Park CK; Choi SH
    Radiology; 2024 May; 311(2):e233120. PubMed ID: 38713025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status.
    Delfanti RL; Piccioni DE; Handwerker J; Bahrami N; Krishnan A; Karunamuni R; Hattangadi-Gluth JA; Seibert TM; Srikant A; Jones KA; Snyder VS; Dale AM; White NS; McDonald CR; Farid N
    J Neurooncol; 2017 Dec; 135(3):601-609. PubMed ID: 28871469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in
    Batchala PP; Muttikkal TJE; Donahue JH; Patrie JT; Schiff D; Fadul CE; Mrachek EK; Lopes MB; Jain R; Patel SH
    AJNR Am J Neuroradiol; 2019 Mar; 40(3):426-432. PubMed ID: 30705071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MR textural analysis on T
    Rui W; Ren Y; Wang Y; Gao X; Xu X; Yao Z
    J Magn Reson Imaging; 2018 Jul; 48(1):74-83. PubMed ID: 29140606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI and CT Identify Isocitrate Dehydrogenase
    Patel SH; Batchala PP; Mrachek EKS; Lopes MS; Schiff D; Fadul CE; Patrie JT; Jain R; Druzgal TJ; Williams ES
    Radiology; 2020 Jan; 294(1):160-167. PubMed ID: 31714193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining methionine-PET and MRI fluid-attenuated inversion-recovery mismatch to determine glioma molecular subtype.
    Ohmura K; Kumagai N; Kumagai M; Ikegame Y; Shinoda J; Yano H; Muragaki Y; Iwama T
    J Neuroimaging; 2023; 33(4):652-660. PubMed ID: 37158779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
    Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
    J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiogenomic association between the T2-FLAIR mismatch sign and IDH mutation status in adult patients with lower-grade gliomas: an updated systematic review and meta-analysis.
    Han Z; Chen Q; Zhang L; Mo X; You J; Chen L; Fang J; Wang F; Jin Z; Zhang S; Zhang B
    Eur Radiol; 2022 Aug; 32(8):5339-5352. PubMed ID: 35169897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiparametric MRI and T2/FLAIR mismatch complements the World Health Organization 2021 classification for the diagnosis of IDH-mutant 1p/19q non-co-deleted/ATRX-mutant astrocytoma.
    Sawlani V; Jen JP; Patel M; Jain M; Haq H; Ughratdar I; Wykes V; Nagaraju S; Watts C; Pohl U
    Clin Radiol; 2024 Mar; 79(3):197-204. PubMed ID: 38101998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining hyperintense FLAIR rim and radiological features in identifying IDH mutant 1p/19q non-codeleted lower-grade glioma.
    Li M; Ren X; Chen X; Wang J; Shen S; Jiang H; Yang C; Zhao X; Zhu Q; Cui Y; Lin S
    Eur Radiol; 2022 Jun; 32(6):3869-3879. PubMed ID: 35079884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiographic assessment of contrast enhancement and T2/FLAIR mismatch sign in lower grade gliomas: correlation with molecular groups.
    Juratli TA; Tummala SS; Riedl A; Daubner D; Hennig S; Penson T; Zolal A; Thiede C; Schackert G; Krex D; Miller JJ; Cahill DP
    J Neurooncol; 2019 Jan; 141(2):327-335. PubMed ID: 30536195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Magnetic resonance imaging texture analyses in lower-grade gliomas with a commercially available software: correlation of apparent diffusion coefficient and T2 skewness with 1p/19q codeletion.
    Kanazawa T; Minami Y; Takahashi H; Fujiwara H; Toda M; Jinzaki M; Yoshida K; Sasaki H
    Neurosurg Rev; 2020 Aug; 43(4):1211-1219. PubMed ID: 31402410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient.
    Maynard J; Okuchi S; Wastling S; Busaidi AA; Almossawi O; Mbatha W; Brandner S; Jaunmuktane Z; Koc AM; Mancini L; Jäger R; Thust S
    Radiology; 2020 Jul; 296(1):111-121. PubMed ID: 32315266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The T2-FLAIR mismatch sign as an imaging marker for non-enhancing IDH-mutant, 1p/19q-intact lower-grade glioma: a validation study.
    Broen MPG; Smits M; Wijnenga MMJ; Dubbink HJ; Anten MHME; Schijns OEMG; Beckervordersandforth J; Postma AA; van den Bent MJ
    Neuro Oncol; 2018 Sep; 20(10):1393-1399. PubMed ID: 29590424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas.
    Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST
    Korean J Radiol; 2021 Feb; 22(2):233-242. PubMed ID: 32932560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.